Ben Enejo

Partner

Areas of Focus

Healthcare & life sciences

Education

Cranfield School of Management

Master of Business Administration

Cranfield University

M.Sc. Molecular Medicine

Nottingham Trent University

B.Sc. Physiology & Pharmacology

Past Experience

PA Consulting Group

Healthcare Management Consultant

Astra Zeneca

Patient Safety Advisor

Janssen Pharmaceuticals (Johnson & Johnson)

Pharmacovigilance Associate

Medical Gases Ltd

Sales Engineer (Business Development)

Ben is a Partner at Arthur D. Little, based in our Boston office, and a member of our global Healthcare & Life Sciences Practice.

Ben is an experienced management consultant and industry expert having worked with various global biopharmaceutical companies on strategies to accelerate the development of new medicines through to commercialization. Particular areas of expertise include clinical trial acceleration, R&D transformation including advanced technology application, increasing success for rare disease drug development and launch, patient and drug safety, and quality and compliance excellence.

Ben holds an MBA with other qualifications in Molecular Medicine, Pharmacology and Physiology, and Program management.

CAR-T (chimeric antigen receptor T-cell) therapy involves the use of genetically re-engineered versions of a patient’s own T-cells to find cancer cells and defeat them. As of March 2020, there are two CAR-T therapies licensed for use – Kymriah® and Yescarta®. CAR-T has pushed the boundaries of medicine, and the success observed in patient treatment has created interest in the use of CAR-T to treat a number of other types of tumors. This is evidenced by the number of clinical trials involving the use of CAR-T to treat a range of cancers (Figures below).

Find out more

Healthcare & life sciences

Managing clinical trials during COVID-19 and beyond

Ben van der Schaaf, Dr. Michael Eiden, Ben Enejo, Craig Wylie, Tom Teixeira, Rick Eagar

One of the many consequences of the COVID-19 crisis has been difficulty in continuing to enroll and run clinical trials, which typically involve large numbers of people interacting in multiple geographies. Arthur D. Little (ADL) has pioneered and deployed a new, risk-based predictive analytical approach, powered by machine-learning technology. It enables pharma companies to make much better predictions and forecasts to support decision-making around key issues, such as adapting patient targets to favor less affected and recovering geographies, program extensions, and new trials.

Find out more